John Theurer Cancer Center, Hackensack, NJ
Martin Gutierrez , Andre Goy , John C. Byrd , Joseph M. Flynn , Morten Sorensen , Peter Brown , Nashat Y. Gabrail , Michael Savona , Ian Flinn , Rachid C. Baz , Bijal D. Shah , Richard M. Stone , Eric Jacobsen , Vishal Kukreti , Roger E. Tiedemann , Tami Rashal , Mansoor Raza Mirza , Sharon Shacham , Michael Kauffman , John Kuruvilla
Background: KPT-330 (Selinexor) is a SINE XPO1 antagonist that forces nuclear retention and activation of >10 tumor suppressor proteins (TSP) and associated with reduction in c-myc and Bcl-XL. Anti-NHL activity was observed in murine models and in spontaneous canine aggressive lymphomas. Methods: Oral KPT-330 was given at 8-10 doses / 28-day cycle. XPO1 inhibition leads to rapid elevations in XPO1 mRNA, representing a pharmacodynamic (PDn) marker for KPT-330. Tumor biopsies were performed. Response evaluation was done in cycles 1, 2, and every 2 cycles. All pts had heavily pretreated NHL with progressive disease (PD) on study entry. Results: Thirty-two pts (18 M, 14 F; median age 68 yrs; ECOG PS 0/1: 9/23; median prior regimens: 3 range 1-11) received KPT-330 across 8 dose levels (3 to 60 mg/m2). Dosing at 60 mg/m2 twice weekly (BIW) is ongoing and MTD has not been reached. Cycle 1 (DLT period) Grade 3/4 events in >1 pt included thrombocytopenia (20%) and neutropenia (20%). The most common grade 1/2 AEs in cycle 1: anorexia (53%), nausea (50%), fatigue (50%), and vomiting (43%). Supportive care with appetite stimulants and anti-emetics diminished constitutional symptoms. Increases in XPO1 mRNA levels were observed at 4-48 hours, supporting BIW dosing. Tumor biopsies confirmed TSP nuclear localization, c-myc reduction, and apoptosis. Objective responses were observed in all histologies of NHL (Table). 5/16 pts have remained on therapy for an average of 9 months (>5-17) months without clinically significant toxicities. Conclusions: KPT-330 is generally well tolerated and can be administered over prolonged periods. The recommended phase 2 dose is ≥45 mg/m2BIW. Durable single agent activity was observed in heavily pretreated NHL pts, and phase 2 studies in DLBCL and Richter’s Syndrome are planned. Clinical trial information: NCT01607892.
NHL | N | PR+SD (%) | PR (%) | SD (%) [%Change in LN Size] |
PD |
---|---|---|---|---|---|
Follicular (FL) | 6 | 6 (100%) | 1 (17%) | 5 (83%) [-17% to -44%] |
– |
Mantle Cell | 2 | 2 (100%) | 1 (50%) | 1 (50%) [-36%] |
– |
DLBCL | 14 | 9 (64%) | 3 (21%) | 6 (43%) [-12% to -19%] |
5 (36%) |
Transformed FL | 3 | 1 (33%) | 1 (33%) | – | 2 (67%) |
Richter's | 3 | 3 (100%) | 1 (33%) | 2 (67%) [-22%] |
– |
Total | 28 | 21 (75%) | 7 (25%) | 14 (50%) | 7 (25%) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2014 ASCO Annual Meeting
First Author: Karen W. L. Yee
2023 ASCO Annual Meeting
First Author: Nehal J. Lakhani
2023 ASCO Annual Meeting
First Author: Jianxiang Wang
2023 ASCO Annual Meeting
First Author: Yanchun Meng